BridgeBio Pharma Total Liabilities 2018-2023 | BBIO
BridgeBio Pharma total liabilities from 2018 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
- BridgeBio Pharma total liabilities for the quarter ending December 31, 2023 were $1.889B, a 1.23% increase year-over-year.
- BridgeBio Pharma total liabilities for 2023 were $1.889B, a 1.23% increase from 2022.
- BridgeBio Pharma total liabilities for 2022 were $1.866B, a 0.71% decline from 2021.
- BridgeBio Pharma total liabilities for 2021 were $1.88B, a 214.7% increase from 2020.
BridgeBio Pharma Annual Total Liabilities
(Millions of US $) |
| 2023 |
$1,889 |
| 2022 |
$1,866 |
| 2021 |
$1,880 |
| 2020 |
$597 |
| 2019 |
$158 |
| 2018 |
$88 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Total Liabilities
(Millions of US $) |
| 2023-12-31 |
$1,889 |
| 2023-09-30 |
$1,850 |
| 2023-06-30 |
$1,854 |
| 2023-03-31 |
$1,839 |
| 2022-12-31 |
$1,866 |
| 2022-09-30 |
$1,857 |
| 2022-06-30 |
$1,876 |
| 2022-03-31 |
$1,854 |
| 2021-12-31 |
$1,880 |
| 2021-09-30 |
$1,520 |
| 2021-06-30 |
$1,539 |
| 2021-03-31 |
$1,483 |
| 2020-12-31 |
$597 |
| 2020-09-30 |
$572 |
| 2020-06-30 |
$580 |
| 2020-03-31 |
$541 |
| 2019-12-31 |
$158 |
| 2019-09-30 |
$119 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.208B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
